BACKGROUND AND OBJECTIVES: Two pivotal randomized controlled trials (RCTs), the Intergroup (INT-0116) and Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trials, demonstrated a survival benefit of multimodality therapy in patients with resectable gastric cancer. The purpose of this study was to determine utilization rates of these treatment regimens in the United States and to identify factors associated with receipt of evidence-based care. METHODS: We performed a retrospective cohort study of patients with Stage IB-IV (M0) gastric adenocarcinoma who underwent resection from 1991 to 2009 using the linked SEER-Medicare database. RESULTS: Only 19.1% of patients received post-operative chemoradiation therapy (CRT), and 1.9% received peri-operative chemotherapy; most patients underwent surgery alone (60.9%). Patients with more advanced stage, younger age, and fewer comorbidities were more likely to receive evidence-based care. We found no association between National Cancer Institute (NCI) designation and delivery of multimodality therapy. However, patients who underwent medical oncology consultation were much more likely to receive evidence-based treatment (OR 3.10, 95% CI 2.35-4.09). CONCLUSIONS: Rates of peri-operative chemotherapy and post-operative CRT in patients with resected gastric cancer remain remarkably low, despite high-quality RCT evidence demonstrating their benefit. Furthermore, NCI designation does not appear to be associated with administration of evidence-based treatment.
BACKGROUND AND OBJECTIVES: Two pivotal randomized controlled trials (RCTs), the Intergroup (INT-0116) and Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trials, demonstrated a survival benefit of multimodality therapy in patients with resectable gastric cancer. The purpose of this study was to determine utilization rates of these treatment regimens in the United States and to identify factors associated with receipt of evidence-based care. METHODS: We performed a retrospective cohort study of patients with Stage IB-IV (M0) gastric adenocarcinoma who underwent resection from 1991 to 2009 using the linked SEER-Medicare database. RESULTS: Only 19.1% of patients received post-operative chemoradiation therapy (CRT), and 1.9% received peri-operative chemotherapy; most patients underwent surgery alone (60.9%). Patients with more advanced stage, younger age, and fewer comorbidities were more likely to receive evidence-based care. We found no association between National Cancer Institute (NCI) designation and delivery of multimodality therapy. However, patients who underwent medical oncology consultation were much more likely to receive evidence-based treatment (OR 3.10, 95% CI 2.35-4.09). CONCLUSIONS: Rates of peri-operative chemotherapy and post-operative CRT in patients with resected gastric cancer remain remarkably low, despite high-quality RCT evidence demonstrating their benefit. Furthermore, NCI designation does not appear to be associated with administration of evidence-based treatment.
Authors: Vikas Dudeja; Greer Gay; Elizabeth B Habermann; Todd M Tuttle; Jennifer F Tseng; Barry W Feig; Waddah B Al-Refaie Journal: Ann Surg Oncol Date: 2011-08-12 Impact factor: 5.344
Authors: Karen L Sherman; Ryan P Merkow; Karl Y Bilimoria; C Edward Wang; Mary F Mulcahy; Al B Benson; David J Bentrem Journal: Ann Surg Oncol Date: 2012-08-14 Impact factor: 5.344
Authors: Paul J Karanicolas; Elena B Elkin; Lindsay M Jacks; Coral L Atoria; Vivian E Strong; Murray F Brennan; Daniel G Coit Journal: J Am Coll Surg Date: 2011-08-26 Impact factor: 6.113
Authors: J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson Journal: N Engl J Med Date: 2001-09-06 Impact factor: 91.245
Authors: Joan L Warren; Linda C Harlan; Angela Fahey; Beth A Virnig; Jean L Freeman; Carrie N Klabunde; Gregory S Cooper; Kevin B Knopf Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Beth A Virnig; Joan L Warren; Gregory S Cooper; Carrie N Klabunde; Nicola Schussler; Jean Freeman Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Rhami Khorfan; Cary Jo R Schlick; Anthony D Yang; David D Odell; David J Bentrem; Ryan P Merkow Journal: J Gastrointest Surg Date: 2019-11-20 Impact factor: 3.452
Authors: Eric M Groh; Shreya Gupta; Zachary J Brown; Lindsey Enewold; Lauren A Gamble; Jonathan M Hernandez; Jeremy L Davis Journal: Ann Surg Oncol Date: 2019-11-20 Impact factor: 5.344
Authors: A L Mahar; A El-Sedfy; M Dixon; M Siddiqui; M Elmi; A Ritter; J Vasilevska-Ristovska; Y Jeong; L Helyer; C Law; B Zagorski; N G Coburn Journal: Curr Oncol Date: 2018-10-31 Impact factor: 3.677
Authors: Ivy N Haskins; Matthew D Kroh; Richard L Amdur; Jeffrey L Ponksy; John H Rodriguez; Khashayar Vaziri Journal: J Gastrointest Surg Date: 2017-07-25 Impact factor: 3.452
Authors: Natalie Liu; Yiwei Xu; Amir A Rahnemai-Azar; Daniel E Abbott; Sharon M Weber; Anne O Lidor Journal: J Gastrointest Surg Date: 2019-12-02 Impact factor: 3.452
Authors: Kelly A Stahl; Elizabeth J Olecki; Matthew E Dixon; June S Peng; Madeline B Torres; Niraj J Gusani; Chan Shen Journal: Curr Oncol Date: 2020-12-24 Impact factor: 3.677